Segall Bryant & Hamill LLC Has $38.20 Million Stock Holdings in Bio-Techne Co. (NASDAQ:TECH)

Segall Bryant & Hamill LLC boosted its holdings in Bio-Techne Co. (NASDAQ:TECH - Free Report) by 17.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 477,880 shares of the biotechnology company's stock after buying an additional 72,011 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.30% of Bio-Techne worth $38,197,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its position in shares of Bio-Techne by 92.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,746,119 shares of the biotechnology company's stock worth $404,470,000 after purchasing an additional 2,755,065 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Bio-Techne by 20.4% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,714,994 shares of the biotechnology company's stock worth $122,879,000 after acquiring an additional 290,510 shares during the last quarter. Mackenzie Financial Corp increased its stake in Bio-Techne by 8.2% during the 2nd quarter. Mackenzie Financial Corp now owns 2,862,260 shares of the biotechnology company's stock valued at $205,081,000 after buying an additional 216,044 shares during the period. Broadcrest Asset Management LLC raised its position in shares of Bio-Techne by 100.0% during the 3rd quarter. Broadcrest Asset Management LLC now owns 200,000 shares of the biotechnology company's stock worth $15,986,000 after buying an additional 100,000 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Bio-Techne by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,589,799 shares of the biotechnology company's stock valued at $185,559,000 after acquiring an additional 88,257 shares in the last quarter. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Scotiabank raised their target price on Bio-Techne from $83.00 to $88.00 and gave the company a "sector outperform" rating in a research note on Thursday, October 31st. StockNews.com raised Bio-Techne from a "hold" rating to a "buy" rating in a research note on Tuesday, November 12th. Royal Bank of Canada cut their target price on shares of Bio-Techne from $72.00 to $70.00 and set a "sector perform" rating for the company in a research report on Thursday, August 8th. Robert W. Baird upped their price target on shares of Bio-Techne from $82.00 to $84.00 and gave the stock an "outperform" rating in a research note on Thursday, October 31st. Finally, Benchmark reissued a "buy" rating and set a $95.00 price objective on shares of Bio-Techne in a research report on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $81.78.

Bio-Techne Stock Performance

Shares of NASDAQ:TECH traded up $2.20 during midday trading on Wednesday, hitting $68.57. The company's stock had a trading volume of 773,719 shares, compared to its average volume of 1,025,223. Bio-Techne Co. has a fifty-two week low of $61.16 and a fifty-two week high of $85.57. The stock has a market capitalization of $10.90 billion, a price-to-earnings ratio of 70.61, a PEG ratio of 4.93 and a beta of 1.28. The stock's 50 day simple moving average is $73.97 and its 200 day simple moving average is $75.35. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.26 and a current ratio of 4.56.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.04. The business had revenue of $289.46 million for the quarter, compared to the consensus estimate of $280.22 million. Bio-Techne had a return on equity of 12.76% and a net margin of 12.86%. The firm's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the business earned $0.35 earnings per share. As a group, research analysts anticipate that Bio-Techne Co. will post 1.68 earnings per share for the current year.

Bio-Techne Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 22nd. Shareholders of record on Monday, November 11th will be paid a dividend of $0.08 per share. The ex-dividend date is Friday, November 8th. This represents a $0.32 annualized dividend and a yield of 0.47%. Bio-Techne's dividend payout ratio is currently 34.04%.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.